Liwu Fu

13.4k total citations · 5 hit papers
209 papers, 9.9k citations indexed

About

Liwu Fu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Liwu Fu has authored 209 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Oncology, 124 papers in Molecular Biology and 24 papers in Cancer Research. Recurrent topics in Liwu Fu's work include Drug Transport and Resistance Mechanisms (83 papers), Cancer therapeutics and mechanisms (46 papers) and HIV/AIDS drug development and treatment (21 papers). Liwu Fu is often cited by papers focused on Drug Transport and Resistance Mechanisms (83 papers), Cancer therapeutics and mechanisms (46 papers) and HIV/AIDS drug development and treatment (21 papers). Liwu Fu collaborates with scholars based in China, United States and Hong Kong. Liwu Fu's co-authors include Fang Wang, Kenneth K.W. To, Zhe‐Sheng Chen, Yong‐ju Liang, Lihua Huang, Zhixing Guo, Sainan An, Lamei Huang, Jianye Zhang and Zhi Shi and has published in prestigious journals such as Nature Communications, SHILAP Revista de lepidopterología and Molecular Cell.

In The Last Decade

Liwu Fu

203 papers receiving 9.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

KRAS mutation: from undruggable to druggable in cancer

2021 599 citations Lamei Huang, Fang Wang et al. Signal Transduction and Targeted Therapy profile →
Mechanisms of resistance to EGFR tyrosine kinase inhibitors

2015 451 citations Liwu Fu et al. profile →
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

2022 210 citations Fang Wang, Liwu Fu et al. profile →
CD39/CD73/A2AR pathway and cancer immunotherapy

2023 204 citations Kenneth K.W. To, Liwu Fu et al. Molecular Cancer profile →
Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy

2025 29 citations Kenneth K.W. To, Liwu Fu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Liwu Fu China	53	5.4k	4.9k	1.4k	1.3k	826	209	9.9k
Kenneth K.W. To Hong Kong	48	4.0k 0.7×	3.2k 0.6×	1.7k 1.2×	766 0.6×	508 0.6×	164	7.5k
Daniel B. Longley United Kingdom	42	7.0k 1.3×	4.7k 1.0×	2.1k 1.5×	1.5k 1.1×	712 0.9×	126	12.1k
Robert W. Robey United States	62	7.3k 1.3×	9.2k 1.9×	1.2k 0.9×	1.0k 0.8×	538 0.7×	159	13.8k
Martin Clynes Ireland	53	5.7k 1.0×	2.8k 0.6×	1.7k 1.2×	854 0.6×	417 0.5×	300	9.0k
Adrian M. Senderowicz United States	45	4.9k 0.9×	3.8k 0.8×	763 0.6×	1.2k 0.9×	602 0.7×	110	8.1k
Liang Cao China	44	4.0k 0.7×	2.1k 0.4×	954 0.7×	848 0.6×	331 0.4×	241	8.0k
Antonio Tito Fojo United States	48	6.9k 1.3×	8.4k 1.7×	1.5k 1.1×	906 0.7×	379 0.5×	137	13.6k
Gergely Szakács Hungary	43	4.7k 0.9×	6.0k 1.2×	769 0.6×	461 0.3×	948 1.1×	141	9.8k
Paola Perego Italy	47	5.8k 1.1×	4.2k 0.8×	1.5k 1.1×	1.3k 1.0×	905 1.1×	177	9.2k
Varsha Gandhi United States	60	6.2k 1.1×	3.7k 0.7×	968 0.7×	1.2k 0.9×	709 0.9×	311	13.5k

Countries citing papers authored by Liwu Fu

Since Specialization

Citations

This map shows the geographic impact of Liwu Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwu Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwu Fu more than expected).

Fields of papers citing papers by Liwu Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liwu Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwu Fu. The network helps show where Liwu Fu may publish in the future.

Co-authorship network of co-authors of Liwu Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Liwu Fu. A scholar is included among the top collaborators of Liwu Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liwu Fu. Liwu Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fu, Liwu, et al.. (2025). Intra-tumoral sphingobacterium multivorum promotes triple-negative breast cancer progression by suppressing tumor immunosurveillance. Molecular Cancer. 24(1). 6–6. 8 indexed citations

To, Kenneth K.W., et al.. (2025). Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion. Advanced Science. 12(12). e2417357–e2417357. 12 indexed citations

Fu, Liwu, et al.. (2025). Association of blood pressure with knee pain progression over 4 years in middle-aged and elderly individuals with or at risks for osteoarthritis: data from the Osteoarthritis Initiative. Clinical Rheumatology. 45(1). 429–440.

Wang, Xueping, Kenneth K.W. To, Min Luo, et al.. (2024). Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis. Signal Transduction and Targeted Therapy. 9(1). 84–84. 15 indexed citations

Wang, Fang, Xiao-Mei Qi, Catherine E. Hagen, et al.. (2020). p38γ MAPK Is Essential for Aerobic Glycolysis and Pancreatic Tumorigenesis. Cancer Research. 80(16). 3251–3264. 63 indexed citations

Fu, Liwu, et al.. (2018). 18F-FDG PET-CT in Unknown-Source of Elevated Serum Carcinoembryonic Antigen (CEA) Level. Journal of College of Physicians And Surgeons Pakistan. 28(12). 910–913. 2 indexed citations

Deng, Cheng‐Cheng, Xiao‐Dong Su, Fang Wang, et al.. (2018). Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR. Cancer Research. 78(13). 3532–3543. 23 indexed citations

Su, Ming‐Yang, Yike Wu, Liwu Fu, et al.. (2018). Circulating Plasma miRNAs as Potential Biomarkers of Non–Small Cell Lung Cancer Obtained by High-Throughput Real-Time PCR Profiling. Cancer Epidemiology Biomarkers & Prevention. 28(2). 327–336. 21 indexed citations

Chen, Yifan, Zhaomin Li, Zizheng Dong, et al.. (2017). 14-3-3σ Contributes to Radioresistance By Regulating DNA Repair and Cell Cycle via PARP1 and CHK2. Molecular Cancer Research. 15(4). 418–428. 27 indexed citations

10.

Zhang, Haipeng, Kai Li, Yuan Lin, et al.. (2017). Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Science Translational Medicine. 9(404). 53 indexed citations

11.

Chen, Zhen, Yifan Chen, Meng Xu, et al.. (2016). Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo , and Ex Vivo. Molecular Cancer Therapeutics. 15(8). 1845–1858. 45 indexed citations

12.

To, Kenneth K.W., et al.. (2016). Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. Lung Cancer. 103. 58–65. 35 indexed citations

13.

To, Kenneth K.W., et al.. (2015). Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon cancer cells to chemotherapy under hypoxia. Biochemical Pharmacology. 97(1). 27–37. 42 indexed citations

14.

He, Jie‐Hua, Sheng Ye, Fang Wang, et al.. (2014). Afatinib Enhances the Efficacy of Conventional Chemotherapeutic Agents by Eradicating Cancer Stem–like Cells. Cancer Research. 74(16). 4431–4445. 45 indexed citations

15.

Zhang, Hui, Atish Patel, Shaolin Ma, et al.. (2014). In vitro, in vivo and ex vivo characterization of ibrutinib: a potent inhibitor of the efflux function of the transporter MRP1. British Journal of Pharmacology. 171(24). 5845–5857. 45 indexed citations

16.

Shi, Zhi, Amit K. Tiwari, Suneet Shukla, et al.. (2011). Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Research. 71(8). 3029–3041. 152 indexed citations

17.

Mi, Yan‐jun, Yong‐ju Liang, Hong-Yun Zhao, et al.. (2010). Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research. 70(20). 7981–7991. 288 indexed citations

18.

Dai, Chun-ling, Yong‐ju Liang, Xu Zhang, et al.. (2009). Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology. 78(4). 355–364. 25 indexed citations

19.

Dai, Chun-ling, Amit K. Tiwari, Chung‐Pu Wu, et al.. (2008). Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research. 68(19). 7905–7914. 333 indexed citations

20.

Fu, Liwu, Yong-ju Liang, & Liming Chen. (2006). Reversal of multidrug resistance by a novel third generation modulator, FG020326.. Cancer Research. 66. 1271–1272. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact